## TREATMENT.COM AI INC. EXTENDS TERM OF MARKETING SERVICES PROVIDED BY 121 MARKETING GROUP

## THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

**Vancouver, British Columbia, March 13, 2025** – Treatment.com Al Inc. (the "**Company**" or "**Treatment**") (CSE: TRUE; OTC: TREIF; FFA: 939) announces that, further to its news release dated January 24, 2025, it has extended the term of marketing and investor awareness services provided by i2i Marketing Group, LLC (i2i") for an additional two (2) months, now expiring on September 23, 2025, in consideration of an additional USD\$200,000.

i2i shall utilize digital marketing and online advertisements through such sites as Google and Bing. i2i does not currently own any interest, directly or indirectly, in the Company or its securities. i2i's address is 1107 Key Plaza #222, Key West, Florida, USA, 33040 (phone: (312) 725-3843, email: contact@i2illc.com). i2i and its directors and officers are arm's length from the Company.

## About Treatment.com Al Inc.

Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: www.treatment.com or email: info@treatment.com

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

ehamza@treatment.com

For media inquiries, contact: media@treatment.com

Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955

## **Cautionary Statement**

This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by

Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.